Cargando…
Bivalent Ligands for Protein Degradation in Drug Discovery
Targeting the “undruggable” proteome remains one of the big challenges in drug discovery. Recent innovations in the field of targeted protein degradation and manipulation of the ubiquitin-proteasome system open up new therapeutic approaches for disorders that cannot be targeted with conventional inh...
Autores principales: | Scheepstra, Marcel, Hekking, Koen F.W., van Hijfte, Luc, Folmer, Rutger H.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Research Network of Computational and Structural Biotechnology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369262/ https://www.ncbi.nlm.nih.gov/pubmed/30788082 http://dx.doi.org/10.1016/j.csbj.2019.01.006 |
Ejemplares similares
-
Discovery of E3 Ligase Ligands for Target Protein Degradation
por: Lee, Jaeseok, et al.
Publicado: (2022) -
The size matters? A computational tool to design bivalent ligands
por: Pérez-Benito, Laura, et al.
Publicado: (2018) -
Examining the influence of specificity ligands and ATP-competitive ligands on the overall effectiveness of bivalent kinase inhibitors
por: Wong, Margaret L., et al.
Publicado: (2017) -
Engineered Bivalent Ligands to Bias ErbB Receptor-mediated Signaling and Phenotypes
por: Jay, Steven M., et al.
Publicado: (2011) -
Key Considerations in Targeted Protein Degradation Drug Discovery and Development
por: Qin, Liena, et al.
Publicado: (2022)